Outlook Therapeutics (OTLK) faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections and a ...

Emotions are constructed, not discovered. Relational safety—not precise labels—allows the brain to tolerate uncertainty, ...

A clear explanation of what Bitcoin is, how it works, and why its decentralized design and fixed supply matter.

Flood of unreality is an endpoint of algorithm-driven internet and product of an economy dependent on a few top tech firms ...

Software engineering is the branch of computer science that deals with the design, development, testing, and maintenance of software applications. Software engineers apply engineering principles and ...

No, Microsoft is not rewriting Windows in Rust. The clarification comes after a LinkedIn post by a Microsoft Distinguished ...

In a quarterly report filed with the U.S. Securities and Exchange Commission on November 14, 2025 ( SEC filing ), TREMBLANT CAPITAL GROUP disclosed a new position in CyberArk Software Ltd.

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

Explore the top antivirus solutions for Windows in 2025, focusing on comprehensive security, compliance, and resilience for enterprises in the evolving threat landscape.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.